None

Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor developed by the Swiss pharmaceutical company Novartis, occupies an important position in the field of breast cancer treatment due to its excellent anti-tumor effect. It can effectively inhibit the growth and proliferation of tumor cells and bring new treatment hope to patients.

In China, everolimus (trade name: Afinitor) has become a key drug in the treatment of malignant tumors such as advanced breast cancer since it was approved for marketing by the State Food and Drug Administration in June 2013. However, as an original drug, its price is relatively high, with each bottle costing about three to four thousand yuan. Although the medical insurance policy can alleviate some of the burden, it is still a large expense for many patient families.

Compared with the domestic version, the Indian version of everolimus has attracted the attention of many patients with its significant price advantage. Thanks to the maturity and cost control of the Indian generic drug industry, the price of the Indian version of everolimus is much lower than that of the original drug. Taking the Indian version of Cipla as an example, the price of each box (5mg*10 tablets) is about eight or nine hundred yuan. The specific price may change due to factors such as exchange rates. This price level can alleviate a lot of financial pressure on patients who require long-term treatment.

Of course, whether they choose original drugs or generic drugs, patients should ensure that they purchase them through formal channels and use them under the guidance of a doctor. During use, if you have any questions or discomfort, you should communicate with your doctor in time to ensure the safety and effectiveness of the treatment.

In general, everolimus, as an important drug in the treatment of breast cancer, is widely used in domestic and foreign markets. Although original drugs are more expensive, the emergence of generic drugs has provided patients with more choices, making treatment more affordable. When choosing, patients should make the decision that best suits them based on their own circumstances and doctor’s recommendations.